Biocon has informed that it has submitted company statement titled ‘Biocon Biologics and Viatris Receive European Commission Approval for Kixelle, Biosimilar Insulin Aspart’. The above information will also be available on the website of the Company at www.biocon.com.
The above information is a part of company’s filings submitted to BSE.